Sentences with phrase «gynecologic cancer in»

Endometrial cancer is the most common type of gynecologic cancer in developed countries.

Cervical cancer is the third most common gynecologic cancer in the United States, and takes the life of one of every three women diagnosed with it.

Not exact matches

Today's guidance, written by a group of cervical cancer screening experts led by University of Alabama at Birmingham gynecologic oncologist Warner Huh, M.D., is being published simultaneously in the journals Gynecologic Oncology, Obstetrics & Gynecology, and the Journal of Lower Genital Tract Disease under the title «Use of Primary High Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance.&cancer screening experts led by University of Alabama at Birmingham gynecologic oncologist Warner Huh, M.D., is being published simultaneously in the journals Gynecologic Oncology, Obstetrics & Gynecology, and the Journal of Lower Genital Tract Disease under the title «Use of Primary High Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidagynecologic oncologist Warner Huh, M.D., is being published simultaneously in the journals Gynecologic Oncology, Obstetrics & Gynecology, and the Journal of Lower Genital Tract Disease under the title «Use of Primary High Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical GuidaGynecologic Oncology, Obstetrics & Gynecology, and the Journal of Lower Genital Tract Disease under the title «Use of Primary High Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance.&Cancer Screening: Interim Clinical Guidance.»

«Estimating from various studies that looked at increasing BMI and endometrial cancer risk, a woman with a Body Mass Index (BMI) of 40 would have approximately eight times greater risk of endometrial cancer than someone with a BMI of 25,» said first author Kristy Ward, MD, the senior gynecologic oncology fellow in the Department of Reproductive Medicine at UC San Diego School of Medicine.

The combination of drugs appeared less toxic than standard chemotherapy, were relatively inexpensive and should be clinically evaluated, said Dwayne G. Stupack, PhD, the study's senior author and associate professor in the dDivision of Gynecologic Oncology at Moores Cancer Center.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

The trial was run by Professor Bradley J. Monk MD who directs the Division of Gynecologic Oncology at the University of Arizona Cancer Center at St. Joseph's in Phoenix and sponsored by Amgen.

In the Phase II clinical trial, Dr. Miller and colleagues in the National Cancer Institute - supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 monthIn the Phase II clinical trial, Dr. Miller and colleagues in the National Cancer Institute - supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 monthin the National Cancer Institute - supported Gynecologic Oncology Group found that in patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 monthin patients who had not received prior chemotherapy, the combination cocktail had a 31 percent response rate for up to 7 months, and an overall survival of 12 months.

Another student who was using phage - display technology to identify new molecular markers in ovarian cancer attended a clinic in gynecologic oncology once a week throughout her dissertation research.

More than one - third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women.

«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author ongynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author onGynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.

Our findings suggest that abstinence from regular physical activity is associated with increased odds of cervical cancer,» says J. Brian Szender, MD, MPH, lead author of the study and a fellow in the Department of Gynecologic Oncology at Roswell Park.

For women with ovarian cancer, a particularly deadly form of gynecologic cancer, even improvements in treatment outcomes have been elusive.

Based on a calculation called the «Risk of Ovarian Cancer Algorithm,» women were divided into three groups: those who should receive another CA125 test one year later (low risk), those who should receive a repeat CA125 in three months (intermediate risk), and those who should receive a transvaginal ultrasound and be referred to a gynecologic oncologist (high risk).

«Now that we know exactly how changes in EMSY spur cancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,» says senior author Douglas Levine, MD, director of the Division of Gynecologic Oncology at NYU Langone and its Perlmutter Cancer Ccancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,» says senior author Douglas Levine, MD, director of the Division of Gynecologic Oncology at NYU Langone and its Perlmutter Cancer CCancer Center.

In 2013, the Society of Gynecologic Oncology recommended the removal of the fallopian tubes during routine hysterectomies, a procedure called opportunistic salpingectomy, in order to reduce the risk of ovarian canceIn 2013, the Society of Gynecologic Oncology recommended the removal of the fallopian tubes during routine hysterectomies, a procedure called opportunistic salpingectomy, in order to reduce the risk of ovarian cancein order to reduce the risk of ovarian cancer.

This study adds to the discussion about the role of this immunosurveillance in the risk of developing the common cancers among those with compromised immune systems,» adds first author Paul Mayor, MD, Fellow in the Department of Gynecologic Oncology at RPCI.

«Unfortunately, due to the lack of screening mechanisms for many gynecologic cancers, they are often diagnosed in an advanced stage, thus leading to poor treatment response with standard therapies in many cases.

As part of an ongoing clinical trial at Rutgers Cancer Institute exploring rare and poor prognosis cancers, investigators sought to identify genomic alterations in 69 patients with gynecologic cancers that were not responding to standard care.

The researchers» next steps will involve expansion of the biomarkers identified in this study to other cancer types, especially breast cancer, due to the hormonal input that is a common factor in gynecologic tumors.

Ovarian cancer is the fifth leading cause of cancer death in women, the leading cause of death from gynecologic malignancies and the second most commonly diagnosed gynecologic malignancy.

Our approach is to study more than one or two serial recurrences of the disease, adding information about the response to therapy and natural progress of ovarian cancer,» adds J. Brian Szender, MD, MS, senior author and a fellow in Gynecologic Oncology at RPCI.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medcancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of MedCancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Brian M. Slomovitz, M.D., co-leader of the Gynecologic Cancers Site Disease Group at Sylvester Comprehensive Cancer Center, received the 2018 Presidential Abstract Award from the Society for Gynecologic Oncology on March 24 during the group's Annual Meeting on Women's Cancer in New Orleans.

In my laboratory at NYU Langone, I focus on precision medicine, rare tumors, and early detection and prevention of gynecologic cancers.

I am a board - certified gynecologic oncologist who specializes in the surgical treatment of women with known or suspected ovarian and endometrial cancers.

Her professional and research interests include familial gynecologic cancers; cancer susceptibility in rare genetic syndromes; and psychosocial counseling in cancer - prone families.

Both Carpen and Soto were referred to Ghadir Salame, MD, a member of NYU's Perlmutter Cancer Center who has earned a well - regarded reputation among obstetric and gynecologic colleagues in the New York metro region for his expertise in treating endometrial cancer using robot - assisted suCancer Center who has earned a well - regarded reputation among obstetric and gynecologic colleagues in the New York metro region for his expertise in treating endometrial cancer using robot - assisted sucancer using robot - assisted surgery.

The results suggest that assessing baseline QoL in women with PRR - ROC might help identify which patients are unlikely to benefit from palliative chemotherapy, said lead study author Felicia Roncolato, MBChB, FRACP, of St. George Hospital in Sydney, Australia, on behalf of the Gynecologic Cancer Intergroup Symptom Benefit Group.

The registry tracks the medical history of patients with specific gynecologic cancers who may have been exposed to diethylstilbestrol (DES) or other synthetic hormones while still in their mother's womb.

Viswanathan, considered the preeminent expert in gynecologic radiation therapies, developed MRI - guided brachytherapy for cervical cancer and other gynecologic cancers.

My primary research focus has been in the use of individualized approach in the management of gynecologic cancer, extremity soft tissue sarcoma through molecular markers and precision radiotherapy.

Patients are treated by a multi-disciplinary team that may include medical oncologists, radiation oncologists, surgical oncologists, neuro oncologists, internal medicine, family practice and radiology; board certified surgeons who are specialists in reconstructive, gynecologic, urologic and neurologic surgery; nurses specially trained in cancer treatment and certified to administer chemotherapy, counselors, who address a full range of psychosocial needs from diagnosis through bereavement; clergy to support all faiths; physical, occupational, speech and nutritional therapists.

The evolution of cancer treatment continues, particularly in the area of gynecologic cancers.

At UT Southwestern Medical Center, our gynecologic cancer experts have unmatched expertise in treating patients with ovarian cancer.

Our specialists are experienced in detecting and treating gynecologic cancers with the latest medical and surgical treatments.

Here, Kebria, gives us a preview of his panel and shares information about advances in combating gynecologic cancers:

We are in an exciting era of discoveries and advances in cancer treatment, specifically with regard to gynecologic cancers.

Our gynecologic cancer specialists combine training and expertise in gynecology, surgery and oncology.

It clearly shows that those who had maintenance [Avastin] had improved profession - free survival,» said Dr. Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. «I think we have to wait for longer term outcomes before we make definite conclusions.

Every year, 10,000 U.S. women are diagnosed with cervical cancer, and 3,600 die from the disease, according to Debbie Saslow, PhD, director of breast and gynecologic cancer at the American Cancer Society in Atcancer, and 3,600 die from the disease, according to Debbie Saslow, PhD, director of breast and gynecologic cancer at the American Cancer Society in Atcancer at the American Cancer Society in AtCancer Society in Atlanta.

He is director of the division of gynecologic oncology at the Perlmutter Cancer Center, which is part of NYU Langone Health in New York City.

«This study confirms that long - term use [of the pill] causes a profound reduction in the risk of ovarian and endometrial cancers,» said Dr. Stephen Rubin, chief of gynecologic oncology at Fox Chase Cancer Center in Philadelphia.

In an interdisciplinary collaboration, the University of Pennsylvania School of Veterinary Medicine's Working Dog Center (photo above courtesy of University of Pennsylvania), the School of Arts and Science's Department of Physics and Astronomy, Penn Medicine's Division of Gynecologic Oncology, and the Monell Chemical Senses Center have joined together for a research investigation using canine olfaction, along with chemical and nanotechnology analysis, to detect early - stage human ovarian cancer.

She has defended health care providers in cases involving alleged birth trauma injuries, cancer misdiagnosis, surgical related incidents, obstetrics, gynecologic matters, radiological related incidents, and various other medical specialties such as pediatrics, infectious disease, neurology, and orthopedics.

Plaintiff deposed defendant's gynecologic pathologist expert over two days during which the expert could not point to a single report in the medical literature to support his belief that the plaintiff already had advanced ovarian cancer prior to her first visit with the defendant.

He has defended clinical laboratories and other healthcare providers and institutions in litigation arising out of gynecologic, skin, breast, and other cancers; neurological birth defects; chromosomal abnormalities; blood disorders; genetic diseases; wrongful birth; terminations of pregnancy; and drug abuse.

About Youtuber The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologGynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologicgynecologic cancers.